Gambia vs Mauritania: Number of people requiring preventive treatment for schistosomiasis
Gambia
657,160 people
in 2024
Mauritania
596,151 people
in 2024
Gambia rank
37th
Mauritania rank
38th
Number of people requiring preventive treatment for schistosomiasis over time
- Gambia
- Mauritania
How they compare
Gambia currently reports 657,160 people against 596,151 people in Mauritania, a difference of 61,009 people.
That makes Gambia's figure about 1.1 times Mauritania's.
The two have swapped places 1 time across 15 shared years of data; in 2010 it was Mauritania ahead.
Gambia ranks 37th and Mauritania ranks 38th of 52 countries.
Mauritania has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Gambia | Mauritania | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 158,622 people | 706,396 people | 547,775 people | Mauritania |
| 2020s | 439,450 people | 849,983 people | 410,533 people | Mauritania |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher number of people requiring preventive treatment for schistosomiasis, Gambia or Mauritania?
- Gambia, at 657,160 people against 596,151 people in Mauritania as of 2024.
- What is the difference in number of people requiring preventive treatment for schistosomiasis between Gambia and Mauritania?
- 61,009 people, with Gambia ahead.
- How many years of comparable data are there for Gambia and Mauritania?
- 15 years are reported by both, from 2010 to 2024.
- How do Gambia and Mauritania rank globally for number of people requiring preventive treatment for schistosomiasis?
- Gambia ranks 37th and Mauritania ranks 38th of 52 countries.
- Where does this data come from?
- World Health Organization (2025) – with minor processing by Our World in Data, published as Number of people requiring preventive treatment for schistosomiasis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Population requiring preventive chemotherapy for schistosomiasis.